Longevity.Technology covers Immorta Bio's short peptide aimed at so-called zombie cells, the aging cells linked to age-related decline.
Recap by typeshit. Full story at Longevity.Technology.
Researchers are starting to explain the shifts in libido some GLP-1 users report. The full story covers what scientists have found so far.
Bikman says the added glucagon receptor push raises energy use and liver fat burning, and points to 24.2% weight loss on 12 mg in phase 2.
9:08
Archibald takes on a common question about low retatrutide doses and the drug's glucagon action. His view, not settled science, and retatrutide is still unapproved.
A report says an Eli Lilly drug helped protect muscle mass when combined with Novo's Wegovy, addressing a common worry about lean mass loss.
10:49
xitsnemox posts a short check-in from week 14 on oral Wegovy, two weeks after stepping up to the 25mg tablet. A personal account, not medical advice.
Only 493 people across eight small trials. The two with the most weight loss, on semaglutide and high-dose liraglutide, both reported lower spine and hip bone density.
Loading…